Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 5Neoplasms 3Colorectal Neoplasms 3Neoplasm Metastasis 2Liver Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumors 1Sarcoma 1Rectal Neoplasms 1Pyloric Stenosis, Hypertrophic 1Endometrial Adenocarcinoma 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 38Fluorouracil 37Radiotherapy 33Oxaliplatin 23Paclitaxel 20Irinotecan 18Leucovorin 17Docetaxel 17Capecitabine 10Neoadjuvant Therapy 9Surgical Procedures, Operative 8Cetuximab 8Chemotherapy, Adjuvant 7Radiation 6Carboplatin 6Immunohistochemistry 5Erlotinib Hydrochloride 5Biopsy 5Magnetic Resonance Spectroscopy 4Gene Expression Profiling 4Folfox protocol 4Epirubicin 4Drug Therapy 4pembrolizumab 3Trastuzumab 3Microarray Analysis 3Gefitinib 3Fluorodeoxyglucose F18 3Endoscopy, Digestive System 3ixabepilone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma Of Esophagus × brivanib × Clear all
NCT00633789 2015-10-09

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Bristol-Myers Squibb

Phase 2 Completed
597 enrolled
GastrointestinalGenitourinarySarcoma

Adenocarcinoma Of Esophagus, Carcinoma, Transitional Cell, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡